The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study
Open accessAbstract
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While similar in distribution, the magnitude of the CBF response in depression patients was distinctly less than that in the study of healthy volunteers by Riba et al. [141].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“Parametric mapping of CBF changes indicated increases in some very small clusters (<50 voxels) localized to the left nucleus accumbens, right insula, and left cingulate cortex, which the authors felt to be regions activated by antidepressant treatments.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“the mean Hamilton depression rating scales declined from 25 to 15 in the three hours after administration, and remained around 10 during the following three weeks.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [142]
In the citing paper
“These open label [22–24] and randomised control [21] trials have suggested that ayahuasca may produce rapid and significant reductions in depression symptoms in as little as 1 day.”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [23]
In the citing paper
“Several studies, including one RCT, have highlighted a similar rapid onset and sustained antidepressant effect after a single ingestion in patients diagnosed with treatment-resistant depression (3, 36).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [36]
In the citing paper
“Similarly, ayahuasca's anti-depressive potential has been demonstrated in pilot studies and replicated in a RCT on patients with treatment-resistant depression (33, 36, 63).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
In the citing paper
“For example, enhanced activation of the ACC and other prefrontal regions was observed in novice and experienced meditators (120–122), and as a result of ayahuasca administration (33, 63).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [33]
Citations
Cites
Pizzagalli, D. A., Holmes, A. J., Dillon, D. G., Goetz, E. L., Birk, J. L., Bogdan, R., Dougherty, D. D., Iosifescu, D. V., Rauch, S. L., & Fava, M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081201 · Cited by 1,232
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
The subgenual anterior cingulate cortex in mood disorders
Drevets, W. C., Savitz, J., & Trimble, M. (2008) · CNS Spectrums · doi:10.1017/s1092852900013754 · Cited by 1,109
A meta‐analytic study of changes in brain activation in depression
Fitzgerald, P. B., Laird, A. R., Maller, J., & Daskalakis, Z. J. (2008) · Human Brain Mapping · doi:10.1002/hbm.20426 · Cited by 903
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Self-citationVollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Research works printed but not linked: 1
- Moreno, 1998, Hamilton (HAM-D) Montgomery Asberg (MADRS) depression rating scales., Rev Psiquiatr Clin, 25, 262
Cited by
Sorted by citations
Items 401–466 of 466
Shaw, L. (2018) · UVic’s Research and Learning Repository (University of Victoria)
Fonseca, A. M., & Rodrigues, E. (2021) · Revista de ciencias farmaceuticas · doi:10.4322/2179-443x.0720
Ayahuasca as a Versatile Therapeutic Agent: From Molecules to Metacognition and Back
Valle, M., Domínguez‐Clavé, E., Elices, M., Pascual, J. C., Soler, J., Morales-Garcia, J. A., Pérez‐Castillo, A., & Riba, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_1
de Oliveira, A. C. S. (2018) · doi:10.47749/t/unicamp.2018.1063092
The good, the bad, and the intoxicated
Mason, N. L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210608nm
The ALSUntangled Group (2017) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2017.1337877
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.10.006
Self-citationKlassieke psychedelica als behandeling voor depressie: waar staan we vandaag?
Slechten, F., & Hert, M. D. H. M. D. (2022) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.075
O parto na luz do Daime: corpo e reprodução entre mulheres na Vila Irineu Serra
Barretto, J. N. R. (2022) · Editora FIOCRUZ eBooks · doi:10.7476/9786557081754
OS POTENCIAIS TERAPÊUTICOS DA AYAHUASCA NO TRATAMENTO DE DEPRESSÃO E ANSIEDADE
Oliveira, J. C. D., Lima, P. V. C., & Pádua, K. D. S. (2022) · Revista Contemporânea · doi:10.56083/rcv2n6-024
Ayahuasca e as pesquisas relacionadas ao contexto religioso: revisão integrativa
Ueno, T. M. R. L., do Nascimento, N. G., de Souza, M. M., Sousa, I. F. R., Garcez, J. C. D., & Martins, A. (2022) · Research Society and Development · doi:10.33448/rsd-v11i17.38784
Should Psychedelic Drugs Be Offered as a Treatment for Mental Illness?
Zhang, R. (2023) · Journal of Humanities Arts and Social Science · doi:10.26855/jhass.2023.02.010
Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen
Becher, L., Nanni, F., & Koslowski, M. (2023) · Nervenheilkunde · doi:10.1055/a-2101-9358
Canale, L., Raval, D., Chatha, P., Penn, K., Weber, C. G., Stout, C., & Weleff, J. (2023) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2023.190103
Medicalisation of Ayahuasca as a Depression Treatment
Cordeiro, E. G. (2023) · The Maastricht Journal of Liberal Arts · doi:10.26481/mjla.2023.v14.912
Can ayahuasca reduce inattention, hyperactivity and impulsivity? A pilot study
Tsang, W., Ruffell, S., Netzband, N., Jong, A., Rucker, J., Deeley, Q., & Hollingdale, J. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231215413
Introduction to the EMBARK Approach
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0006
Bringing It Home and Carrying It Forward
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0009
Considerations Prior to Meeting With a Participant
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0005
INTRODUCTION: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0001
Choosing Suggested Integration Goals
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0004
Working Within the EMBARK Domains Cheat Sheet
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0007
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0002
An Overview of Psychedelic-Assisted Therapy
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0002
Personal Care for the Therapist
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0001
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0008
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.002.0004
EMBARK Mechanisms of Change in the Treatment of Depression
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0004
SANTOS, R. G. D., & Hallak, J. E. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00015-x
Self-citationFármacos enteógenos y la depresión resistente al tratamiento: Una revisión narrativa
Herrera-Solís, A., Morelos, J. C., Ruiz‐Contreras, A. E., Méndez‐Díaz, M., Ortega-Gómez, A., & Prospero-Garcia, O. E. (2024) · PSICUMEX · doi:10.36793/psicumex.v14i1.628 · Cited by 1
Ramarushton, B. (2024) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2332656
Skryabin, V. Y. (2025) · Neurology Bulletin · doi:10.17816/nb639991
Shah, R. J., & Sarangi, A. (2025) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2025.2500345
Assessing novel expectancies about ayahuasca : a preliminary report
Altman, B. R. (2019) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/57py-y18d
McConnell, P., Raffety, J., Li, A., Steinberg, E., Rahim, S., Valtierra, C., Gazzaley, A. H., Carhart-Harris, R. L., & Pasquini, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7625999/v1
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review
de Oliveira, A. L., de Oliveira, D. P., SANTOS, R. G. D., & Hallak, J. E. C. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111534
Self-citationAyahuasca prevents the reinstatement of cocaine-induced rewarding effects in C57Bl/6 mice
Bruno, V., Spelta, L. E. W., Pereira, M. L., Dörr, F., Paranhos, B. A. P. B., Santos, F. P., Yonamine, M., Garcia, R. C. T., Torres, L. H., Pasquale, R. D., et al. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06946-0
Foundations of holistic mental health
Reddy, K. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-43908-7.00007-0
Toscano, M. O., Civardi, S. C., & Durbano, F. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1014070
Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Araújo, D. B., Maia, L. O., Sanchez, T. A., Coelho, N. L. G., & Palhano-Fontes, F. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00721-7
Teixeira, P. J., Encantado, J., Amaro, H. D., Veiga, D., de Carvalho, L. L., Alcázar‐Córcoles, M. Á., Hallak, J. E. C., SANTOS, R. G. D., Bouso, J. C., & Kohek, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2631378
Self-citationPsychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil
Portes, M. A. M., & Bertoglio, L. J. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644865
Bouso, J. C., Andión, Ó., Cantillo, J., Pérez, I. H., Farré, M., Obiols, J. E., & González, D. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100018
Low, Z. X. B. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111717 · Cited by 2
Psychedelics: Future Therapeutics in Major Depression?
Olivier, B., & Olivier, J. D. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_25
A trip through the psychiatric use of psychedelics in Brazil: A scoping review
Kami, V. R., Salle, B. B. B., Porto, G., Cavalari, V. C., & Roza, T. H. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100024
Personalised Perception: The Effect of Personality on the Sensory Effects of Psychedelics
Boardman, A. D., Whelan, J., & Ward, R. D. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70172
Guimarães, A. L., Beserra, F. R., da Cruz, L. V. M., Bienemann, B., FREIND, J. M. K., Guinle, V., Rodrigues, R., Regalado, J. A., & Mograbi, D. C. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.05.012
Ten practical suggestions for setting up a psychedelic study
Caulfield, A., Butler, M., & Mehta, M. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261458350
Estela-Fernandez, C. A., Elsheikh, R. M. Y., Beatrice, D. F., Alhendal, A. A., Ewe, C. I., Montesinos, S. Y., Wensel, J., Mishra, A. P., Yousif, A. A., & Ali, H. T. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00584-4
Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review
Vucak, N., Bruno, R., Quealy, J. J., Casimaty, J. G., Rossell, S. L., Castle, D. J., & Acevedo, N. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100030
Potential Role of Psychedelics in the Treatment of Depressive Disorder
Wang, S., & Bahk, W.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_12
Ogbu, J. I., Moreira, C. V. L., Olusola, A. J., Lacerda, R. F., Maggi, L. E., Filho, A. S. S., Xavier, C. H., Pedrino, G. R., Costa, É. A., & Fajemiroye, J. O. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00472-z
Civardi, S. C., Besana, F., Durbano, F., Toscano, M. O. M., Raffone, F., Dell’Osso, B. M., & Olivola, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1858319
Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward
Mallevays, M., & Berkovitch, L. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113878
Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis
Maekawa, R. M., Guerra, L. T. L., Villanova, B., de Paula, C. C., Vicentini, A. B., Rodrigues, L. S., Reis, J. A. S., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002264
Self-citationFlorineth, G. A., Boeker, A. L., Müller, F., Bracht, T., Denier, N., Jung, A. C., Wopfner, A., Adorjan, K., & Soravia, L. M. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261492600
Corona, C. F., Lima, F. A. A., Sumensse, J. S. C. D. S., Carvalho, K. D., Grignet, P. H., Confortim, H. D., Gross, M. C., Firmino, F. A., Evangelista, F. F., do Nascimento, F. P., et al. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70290
de Paula, C. C., Vicentini, A. B., Guerra, L. T. L., Maekawa, R. M., Reis, J. A. S., Villanova, B., Gomes, C. C., Bellucci, T., Rossi, G. N., Bouso, J. C., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002267
Self-citationBindingDB Entry 50010511: Bioactive Azepine-Indole Alkaloids from
BindingDB (2021) · UC San Diego · doi:10.7270/q27h1p4d
Moskovitz, M. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00402
Metadata
- Authors
- Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Corresponding author
- Sanches, Rafael Faria
- Macedo, Ligia R.H.
- Crippa, José Alexandre S.
- Hallak, Jaime E.C.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2016-02
- Volume
- 36
- Issue
- 1
- Pages
- 77-81
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2419844652
- Cited by
- 466
- References
- 26
- Citations by year
- 2026: 31 · 2025: 34 · 2024: 63 · 2023: 55 · 2022: 68 · 2021: 59 · 2020: 39 · 2019: 28 · 2018: 41 · 2017: 31 · 2016: 14
- FWCI
- 35.96
- Type
- journal article
- Language
- en
- Open access
- green
- repositorio.ufrn.br
- Licence
- other-oa
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ayahuasca, recurrent depression, antidepressant effects, dimethyltryptamine, harmine, 5-HT2A receptor agonism, monoamine oxidase A inhibition, regional cerebral blood flow, nucleus accumbens, insula, dissociative states, adverse effects, single-dose administration
- MeSH terms
- Administration, Oral, Adult, Antidepressive Agents, Brain, Major Depressive Disorder, Female, Hallucinogens, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Time Factors, Tomography, Emission-Computed, Single-Photon, Treatment Outcome, Plant Preparations, Banisteriopsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
